

# Anti-Cytokeratin 7&8 [OV-TL12/30 and C51]

Catalog No.	Description		
AM587-5M	6 ml of Ready-to-Use Antibody for use with BioGenex Super Sensitive <sup>TM</sup> Detection Systems OR equivalent detection system		
AM587-10M	10 ml of Ready-to-Use Antibody in a barcode labeled vial for use with BioGenex Super Sensitive <sup>TM</sup> Detection Systems and i6000 <sup>TM</sup> Automated Staining Systems		
MU587-UC	1 ml of Concentrated Antibody for use with BioGenex Super Sensitive <sup>TM</sup> Detection Systems OR equivalent detection system		
MU587-5UC	0.5 ml of Concentrated Antibody for use with BioGenex Super Sensitive TM Detection Systems OR equivalent detection system		
AX587-YCD	X587-YCD Ready-to-Use Antibody in Barcode labeled vial for use on the Xmatrx <sup>®</sup> Elite/Ultra Staining System, 160 tests		
AX587-50D	Ready-to-Use Antibody in Barcode labeled vial for use on the Xmatrx® Elite/Ultra Staining System, 50 tests		

Clone	Species	Ig Class
OV-TL12/30 and C51	Mouse	IgG

#### **Intended Use**

**For In Vitro Diagnostic Use.** This antibody is designed for the specific localization of Cytokeratin 7&8 in formalin-fixed, paraffin-embedded (FFPE) tissue sections. Evaluation must be performed by a qualified pathologist.

#### **Summary and Explanation**

Cytokeratins are a family of intermediate filament proteins that assemble into filaments through forming heterodimers of one acidic type I cytokeratin (cytokeratins 9 to 23) and one type neutrol-basic II cytokeratin (cytokeratins 1 to 8). Cytokeratin 8 is primarily found in the non squamous epithelia. Cytokeratin 7 is usually present in adenocarcinomas of lung, breast, endometrioid tumors, and transitional cell carcinoma of the bladder. Combination of cytokeratin 7 and 8 is a useful marker for differentiating adenocarcinomas and ductal carcinomas from squamouse cell carcinomas.

#### **Storage and Handling**

**Store at 2-8°C.** Fresh dilutions, if required, should be prepared prior to use and are stable and steady for up to one day at room temperature (20-26°C). Diluted antibody preparations can be refrigerated or frozen for extended shelf life.

# **Principles of the Procedure**

Antigen detection by immunohistochemistry (IHC) is a two-step process wherein the primary antibody binds to the antigen of interest and that binding is detected by a chromogen. The <u>primary antibody</u> may be used in IHC using manual techniques or BioGenex Automated Staining System. Positive and negative controls should always be run simultaneously with all patient specimens.

## **Reagents Provided**

Mouse Monoclonal Antibody to Cytokeratin 7&8 is affinity purified and diluted in PBS, pH 7.2, containing 1% BSA and 0.09% sodium azide.

#### **Dilution of Primary Antibody**

BioGenex Ready-to-Use antibodies have been optimized for use with the recommended BioGenex Detection System and should not require further dilution.

BioGenex concentrated antibodies must be diluted in accordance with the recommended protocol when used with the recommended BioGenex Detection System.

# **Recommended Protocol**

Refer to the following table for conditions specifically recommended for this antibody. Refer to the BioGenex website for guidance on specific staining protocols or other requirements.

Parameter	BioGenex Recommendations		
Control Tissue	BREAST CA as available from BioGenex FB-587M* & FG- 587M*		
Recommended Dilution for Concentrated Antibody	1: 10-20 in HK941		
Recommended Pretreatment (Manual/i6000)**	EZ-AR2 (HK522-XAK)		
Recommended Pretreatment (Xmatrx)	EZ-AR2 Elegance (HX032- YCD)		
Antibody Incubation (Manual/i6000)	30-60 mins at RT		
Antibody Incubation (Xmatrx)	30-60 mins at RT		
Detection System for Manual, Xmatrx & i6000 systems***	Use BioGenex Two-Step <b>OR</b> One-Step Super Sensitive <sup>™</sup> Polymer-HRP IHC Detection System/DAB; see p. 2 for more information		

<sup>\*</sup>FB: positive control barrier slides, FG: positive control non-barrier slides. Xmatrx requires barrier slides.

<sup>\*\*</sup>Pretreatment times will vary based on individual microwave power.

Category	Antibodies	Revision No.	G
Document No.	932-587M-EN	Release Date	May 31, 2021

\*\*\*For automation systems (Xmatrx-Elite, Xmatrx-Ultra & i6000 Diagnostics), refer to the factory protocols provided with the instrument.

Detection	Two-Step	One-Step	Link and	
System	HRP Kit	HRP Kit	Label Kit	
	QD440-XAKE			
	(1000 Test)	QD630-XAKE	QP300-XAKE	
	QD430-XAKE	(1000 Test)	(1000 Test)	
Manual	(1000 Test)			
Ivialiual	QD420-YIKE			
	(500 Test)	QD620-XAKE	QP900-9LE	
	QD400-60KE	(500 Test)	(500 Test)	
	(60 Test)			
Xmatrx -	QD550-YCDE	QD610-YADE	N/A	
Automation	(200 Test)	(200 Test)	IN/A	
i6000 -	QD410-YAXE	QD610-YAXE	N/A	
Automation	(200 Test)	(200 Test)	1 <b>V/</b> /A	
For more information, visit <u>www.biogenex.com</u> .				

#### **Precautions**

This product contains sodium azide at concentrations of less than 0.1%. Sodium azide is not classified as a hazardous chemical at the product concentrations, but proper handling protocols should be observed. For more information, a Safety Data Sheet (SDS) for sodium azide is available upon request. Dispose of unused reagents according to Local, State and Federal Regulations. Wear suitable Personal Protective Equipment, do not pipette reagents by mouth, and avoid contact of reagents and specimens with skin and mucous membranes. If reagents or specimens come in contact with sensitive area, wash with copious amounts of water.

#### **Ouality Control**

Refer to BioGenex detection system documents for guidance on general quality control procedures.

# **Troubleshooting**

Refer to the troubleshooting section in the documentation for BioGenex Detection Systems (or equivalent detection systems) for remedial actions on detection system related issues, or contact BioGenex Technical Support Department at 1-800-421-4149 or support@biogenex.com or your local distributor to report unusual staining.

# **Expected Results**

This antibody stains cytoplasm in positive cells in formalinfixed, paraffin embedded tissue sections. An example image of a tissue section stained with this antibody can be found on the product page on the BioGenex website. Interpretation of the staining result is solely the responsibility of the user. Experimental results should be confirmed by a medicallyestablished diagnostic product or procedure.

#### Limitations of the Procedure

Improper tissue handling and processing prior to immunostaining can lead to inconsistent results. Variations in embedding and fixation or the nature of the tissue may lead to variations in results. Endogenous peroxidase activity or pseudo peroxidase activity in erythrocytes and tissue biotin may result in non-specific staining based on the detection system employed. Tissues containing Hepatitis B Surface Antigen (HBsAg) may give false positive with horseradish peroxidase systems. Improper counterstaining and mounting may compromise the interpretation of results.

# **Bibliography**

- 1. Moll R, et al. Cell 1982; 31:11-24.
- 2. Ramaekers F, et al. Am J Pathol 1990; 136:641-655.
- 3. Schaafsma, H.E., et al. Am J Pathol 1990; 136:329-343.
- 4. Center for Disease Control. Decontamination of Laboratory Sink Drains to Remove Azide Salts. Center Disease Control Manual Guide--Safety Management, No. CDC-22, Atlanta, Georgia. April 30, 1976.

2°C 8°C	Temperature Limitation	IVD	In Vitro Diagnostic Medical Device
$\boxtimes$	Use By Date	LOT	Batch Code
NON STERILE	Non-Sterile	<u>i</u>	Consult Instructions for Use
EC REP	Representative in the European Community	***	Manufacturer

© 2020, BioGenex Laboratories. All rights reserved.

Category	Antibodies	Revision No.	G
Document No.	932-587M-EN	Release Date	May 31, 2021